Kissejte s tüdorákban szenve do betegek hatéko ny eritropoet ikus prote in ke zel ése - Saját tapasztalatok

Translated title of the contribution: Erythropoietic protein supportive treatment in small cell lung cancer

Research output: Contribution to journalArticle


Anemia is common among patients with malignant tumors, due to the disease and chemotherapy. Anemia decreases patient's quality of life, and worsens the dose intensity of chemotherapy. The aim of this retrospective data-analysis was to determine the rate of transfusions and the maintenance of chemotherapeutic dose intensity in 9 small cell lung cancer patients receiving beta-erythropoietin, due to anemia observed after the first cycle of chemotherapy. The mean pre-treatment hemoglobin concentration of the patients was 116.67±8.17 g/L (mean±SD). The mean pre-erythropoietin hemoglobin concentration at baseline was 103.11±7.52 g/L. Six cycles of platina-etoposid were used. The post-treatment hemoglobin concentration of patients was 110.11±5.37 g/L (p=0,028 vs. baseline). During these 54 chemotherapeutic cycles, only 2 patients needed transfusion, each of them once. According to our experience, the use of beta-erythropoietin in 9 anemic small cell lung cancer patients resulted in a low rate of transfusions and maintenance of cytotoxic treatment dose intensity. The adequate use of beta-erythropoietin is of great help to the physician in the management of small cell lung cancer patients.

Translated title of the contributionErythropoietic protein supportive treatment in small cell lung cancer
Original languageHungarian
Pages (from-to)43-46
Number of pages4
JournalMagyar onkologia
Issue number1
Publication statusPublished - Dec 1 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Erythropoietic protein supportive treatment in small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this